Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (1-10 of 301) with videos related to

Pageof 31
Sort By:
Hematology. American Society of Hematology. Education Program|December 6, 2015
Maintenance therapy for multiple myeloma in the era of novel agentsThierry Facon
Clinical Advances in Hematology & Oncology : H&O|December 7, 2006
Advances in the treatment of elderly patients with multiple myelomaThierry Facon
Presse Medicale (Paris, France : 1983)|January 24, 2025
EditorialThierry Facon
The New England Journal of Medicine|January 29, 2025
Isatuximab-Based Therapy for Multiple Myeloma. ReplyThierry Facon
La Revue Du Praticien|February 21, 2002
[Multiple myeloma of the bone]Thierry Facon
Best Practice & Research. Clinical Haematology|December 12, 2007
Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantationThierry Facon, Stéphane Darre
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|August 26, 2022
Platelet transfusion in adults: more to know?France Pirenne, Thierry Facon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2025
Rewriting Risk: A Data-Driven Look at Myeloma GeneticsKrina Patel, Thierry Facon
Hematology. American Society of Hematology. Education Program|December 4, 2018
Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologistThierry Facon, Kenneth Anderson
Leukemia|May 4, 2018
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agentsHerve Avet-Loiseau, Thierry Facon
Pageof 31

Showing results (1-10 of 301) with videos related to

Sort By:
Pageof 31
Hematology. American Society of Hematology. Education Program|December 6, 2015
Maintenance therapy for multiple myeloma in the era of novel agentsThierry Facon
Clinical Advances in Hematology & Oncology : H&O|December 7, 2006
Advances in the treatment of elderly patients with multiple myelomaThierry Facon
Presse Medicale (Paris, France : 1983)|January 24, 2025
EditorialThierry Facon
The New England Journal of Medicine|January 29, 2025
Isatuximab-Based Therapy for Multiple Myeloma. ReplyThierry Facon
La Revue Du Praticien|February 21, 2002
[Multiple myeloma of the bone]Thierry Facon
Best Practice & Research. Clinical Haematology|December 12, 2007
Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantationThierry Facon, Stéphane Darre
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|August 26, 2022
Platelet transfusion in adults: more to know?France Pirenne, Thierry Facon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2025
Rewriting Risk: A Data-Driven Look at Myeloma GeneticsKrina Patel, Thierry Facon
Hematology. American Society of Hematology. Education Program|December 4, 2018
Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologistThierry Facon, Kenneth Anderson
Leukemia|May 4, 2018
Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agentsHerve Avet-Loiseau, Thierry Facon
Pageof 31